The Venture Codex Logo

The Venture Codex

Royalty Pharma

110 East 59th Street, Suite 3300, New York, NY, 10022, United States

Overview

Acquires royalty interests in biopharmaceutical products for liquidity.

Deals ยท 12mo

0

Links

WebsiteLinkedIn

Stage focus

Series B

Geographic focus

United States

Sector focus

Biotechnology
Manufacturing
Pharmaceutical

Investment portfolio

1rounds
NAMEDATESIZE
Kailera Therapeutics
Oct 2025Participated
$600 MSeries B
Kailera Therapeutics
Oct 2025Participated
$600 MSeries B
1
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Royalty Pharma: 1 funding rounds are recorded in the selected participation categories.All available history.
Royalty Pharma: 1 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series B01

Monthly Deal Activity

Royalty Pharma: 1 deals are recorded across 13 months.All available history.
Royalty Pharma: 1 deals are recorded across 13 months. All available history
MonthDeals
Oct '251
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Royalty Pharma: Health & Life Sciences is the largest displayed sector by deal count (1 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Royalty Pharma: Health & Life Sciences is the largest displayed sector by deal count (1 deals). All available history
SectorDeals
Health & Life Sciences1

Deal Size Distribution

Royalty Pharma: 1 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Royalty Pharma: 1 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M0
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B1
$1B+0

Deals By Geography

Royalty Pharma: United States has the largest recorded deal count among the displayed regions (1 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Royalty Pharma: United States has the largest recorded deal count among the displayed regions (1 deals). All available history
RegionDeals
United States1
Royalty Pharma: 13 co-investors are shown, with Adage Capital Management sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Royalty Pharma: 13 co-investors are shown, with Adage Capital Management sharing 1 recorded deals. All available history
Co-investorShared deals
Adage Capital Management1
Atlas Venture1
Bain Capital Life Sciences1
Bain Capital Private Equity1
Canada Pension Plan Investment Board1
Invus1
Janus Henderson Investors1
Perseverance Capital Management1
Qatar Investment Authority1
RTW Investments1
Sirona Capital1
Surveyor Capital1
T. Rowe Price Associates1

Investment Strategy

Royalty Pharma: Led accounts for 0% and participating for 100% of round participation.All available history.
Royalty Pharma: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating1100%
Royalty Pharma: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
Royalty Pharma: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Eric Schneider

Senior Vice President and Chief Technology Officer

George Lloyd

Executive Vice President, Investments and General Counsel

Jim Reddoch, PhD

Chief Scientific Officer, Executive Vice President, Head of Research and Investments

Pablo Legorreta

CEO & Founder

Sandy Balkin

SVP Strategy and Analytics